Quarterly guidance

Quarterly guidance
No specific quarterly guidance was provided.

Annual guidance

Operational sales growth
6.7% to 7.1%
Reported sales growth
7.2% to 7.6%
Adjusted operational EPS
$10.95 to $11.05
Reported adjusted EPS
$11.05 to $11.15

Outlook

Growth trajectory
Management expects to achieve double-digit growth by the end of the decade through internal strategic investments.
MedTech recovery
Management expects improved performance in the fourth quarter and beyond, driven by U.S. momentum and the moderation of international headwinds.
Oncology pipeline
The company expects several important data readouts in the fourth quarter, including pasritamig and J&J-6143.
MedTech innovation
The company plans to build adoption and revenue contribution for the Ottava robotic system over time.
Currency impact
Assuming current spot rates hold, management expects currency to be a headwind for the next year.